a b s t r a c t
The interaction between NMDA receptors and m-opioid receptors in primary afferent terminals was studied by using NMDA to induce substance P release, measured as neurokinin 1 receptor internalization.
In rat spinal cord slices, the m-opioid receptor agonists morphine, DAMGO and endomorphin-2 inhibited NMDA-induced substance P release, whereas the antagonist CTAP right-shifted the concentration response of DAMGO. In vivo, substance P release induced by intrathecal NMDA after priming with BDNF was inhibited by DAMGO. u-Conotoxins MVIIC and GVIA inhibited about half of the NMDA-induced substance P release, showing that it was partially mediated by the opening of voltage-gated calcium (Cav) channels. In contrast, DAMGO or u-conotoxins did not inhibit capsaicin-induced substance P release. In cultured DRG neurons, DAMGO but not u-conotoxin inhibited NMDA-induced increases in intracellular calcium, indicating that m-opioid receptors can inhibit NMDA receptor function by mechanisms other than inactivation of Cav channels. Moreover, DAMGO decreased the u-conotoxin-insensitive component of the substance P release. Potent inhibition by ifenprodil showed that these NMDA receptors have the NR2B subunit. Activators of adenylyl cyclase and protein kinase A (PKA) induced substance P release and this was decreased by the NMDA receptor blocker MK-801 and by DAMGO. Conversely, inhibitors of adenylyl cyclase and PKA, but not of protein kinase C, decreased NMDA-induced substance P release. Hence, these NMDA receptors are positively modulated by the adenylyl cyclase-PKA pathway, which is inhibited by m-opioid receptors. In conclusion, m-opioid receptors inhibit NMDA receptor-induced substance P release through Cav channel inactivation and adenylyl cyclase inhibition.
Published by Elsevier Ltd.
NMDA receptors in the spinal dorsal horn play a key role in chronic pain and central sensitization (Kim et al., 2012; Randic et al., 1993; Woolf and Thompson, 1991) . NMDA receptors are present in primary afferents (Li et al., 2004; Liu et al., 1994; Lovinger and Weight, 1988; Ma and Hargreaves, 2000; Marvizon et al., 2002; McRoberts et al., 2007) and evoke the release of substance P from their central terminals Malcangio et al., 1998; Marvizon et al., 1997) . Conversely, substance P release from primary afferents is inhibited by m-opioid receptors (MORs) (Kondo et al., 2005; Yaksh et al., 1980; Zhang et al., 2010) , d-opioid receptors (DORs) (Zachariou and Goldstein, 1996a) and k-opioid receptors (KORs) Goldstein, 1996b, 1997) . In the latent sensitization model of chronic pain, spinal cord hyperalgesia is maintained by NMDA receptors (Corder et al., 2013; Laulin et al., 2002; Richebe et al., 2005) and suppressed by MORs, DORs and KOR (Campillo et al., 2011; Corder et al., 2013; Walwyn et al., 2016) . This suggests that the interaction between NMDA receptors and opioid receptors plays an important role in regulating nociceptive transmission between primary afferents and dorsal horn neurons.
Our goal was to investigate the mechanisms involved in the inhibition by MORs of NMDA receptor-evoked substance P release. We used neurokinin 1 receptor (NK1R) internalization in dorsal horn neurons as a measure in situ of substance P release and NK1R activation, an approach used and validated in numerous studies (Adelson et al., 2009; Liu et al., 1997; Mantyh et al., 1995; Marvizon et al., 1997 Marvizon et al., , 2003a . In previous reports we have shown that NMDAinduced substance P release is mediated by NMDA receptors because it was inhibited by the NMDA receptor antagonist 2-amino-phosphopentanoic acid and by its channel blocker MK-801 Marvizon et al., 1997) . We also showed that substance P was released from primary afferents terminals, since it disappeared after depleting them of substance P with capsaicin. The NMDA receptors that induce substance P release are also present in the presynaptic terminals of primary afferents, because 1) the release was not affected by blocking action potentials with lidocaine , and 2) NMDA-induced substance P release was substantially decreased in mice with selective knockdown of NMDA receptors in nociceptive primary afferents expressing Nav1.8 channels (Chen et al., 2014) .
We considered the following mechanisms that could mediate the inhibition of these NMDA receptors by MORs. 1) Inactivation of voltage-gated Ca 2þ (Cav) channels (Heinke et al., 2011; Moises et al., 1994; Rusin and Moises, 1995) , which would require that Cav channels activated by depolarization contribute to NMDA receptorinduced release. 2) Inhibition of the adenylyl cyclase (AC) -protein kinase A (PKA) pathway, since NMDA receptors with the NR2B subunit requires PKA phosphorylation at Ser 1166 (Murphy et al., 2014) . 3) Opening G protein-gated inwardly rectifying K þ (GIRK) channels (Gao et al., 2007; Marker et al., 2005) , which would produce a hyperpolarization that would inhibit of the NMDA receptors.
4) The direct physical association of MORs and NMDA receptors, which increases morphine analgesia by inhibiting NMDA receptors Rodríguez-Muñoz et al., 2008 2012) . We previously reported (Chen et al., 2014 ) that induction of substance P release by NMDA receptors in vivo requires the activation of tropomyosin-related kinase B (trkB) receptors by brainderived neurotrophic factor (BDNF), which occurs after nerve injury. This is consistent with the finding that NMDA receptors increase primary afferent glutamatergic neurotransmission in nerve-injured rats (Yan et al., 2013) but not in normal rats (Bardoni et al., 2004; Yan et al., 2013; Zeng et al., 2006) . BDNF triggers the phosphorylation of the NR2B subunit at Tyr 1472 by Src family kinases (SFKs), which increases substance P release . Hence, we also studied how opioid agonists and BDNF interact to regulate NMDA receptor-induced substance P release.
1. Material and methods
Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee of the Veteran Affairs Greater Los Angeles Healthcare System and the Animal Research Committee of UCLA, and conform to NIH guidelines. Efforts were made to minimize the number of animals used and their distress. Rats used were male adult (2e4 months old) Sprague-Dawley (Harlan, Indianapolis, IND).
Chemicals
8-Br-cAMP, brain-derived neurotrophic factor (BDNF), BVT948, chelerythrine, u-conotoxin (CTX) MVIIC, CTX GVIA, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP), [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin (DAMGO), endomorphin-2, forskolin, KT5720, phorbol 12-myristate 13-acetate, protein kinase inhibitor 14e22 (PKI 14e22), Ro-32-0432, SQ22536, tertiapin-Q and TPPB were from Tocris (Ellisville, MO); morphine sulfate was from Baxter; other compounds were from Sigma. Drugs were prepared as stock solutions of 1e10 mM in the appropriate solvent (DMSO or water) and then diluted in aCSF.
Spinal cord slices
Spinal cord slices were prepared as described (Adelson et al., 2009 ). The spinal cord was extracted from adult rats after euthanasia with pentobarbital (0.15e0.2 ml of Fatal Plus, Vortech Pharmaceuticals, Dearborn, Michigan, corresponding to 58e78 mg of pentobarbital per rat). Coronal slices (400 mm, 3e8 per rat) were cut from the lumbar spinal cord (L2-L4) with a vibratome (Integraslice 7550PSDS, Lafayette Instruments, Lafayette, IN) using low advance 
phenyl]-2,4-pentadienamide TRPV1 transient receptor potential vanilloid 1 speed and fast vibration. For electrical stimulation of the dorsal root, slices had one dorsal root longer than 8 mm. Contact between the root and the slice was assessed with a stereomicroscope to ensure that at least 80% of the dorsal funiculus was continuous with dorsal root fibers. Slices were kept in artificial cerebrospinal fluid (aCSF), which contained (in mM) 124 NaCl, 1.9 KCl, 26 NaHCO 3 , 1.2 KH 2 PO 4 , 1.3 MgSO 4 , 2.4 CaCl 2 and 10 glucose, and was bubbled with 95% O 2 /5% CO 2 . Vibratome cutting was done in sucrose-aCSF, which was the same medium with 5 mM KCl and 215 mM sucrose instead of NaCl. Slices were left to recover in oxygenated aCSF at 35 C for 1 h and were used within 3 h.
Slices were incubated with drugs using established procedures (Marvizon et al., 2003a (Marvizon et al., , 2003b . The slices were placed on a nylon net glued to a plastic ring inserted halfway down a plastic tube containing 5 ml aCSF, which was kept at 35 C using a metal block incubator (IncuBlock, Denville Scientific Inc., Metuchen, NJ). The aCSF was superficially gassed with 95% O 2 /5% CO 2 delivered through a needle inserted through the cap of the tube. This arrangement ensured access of oxygenated aCSF and drugs from both sides of the slice. To change solutions, the ring and net with the slice was transferred to another tube. To avoid possible excitotoxic effects, NMDA and D-serine were applied to the slices only for 2 min.
Electrical stimulation of the dorsal root was performed as described (Adelson et al., 2009) . It consisted of 1000 electrical square pulses of 20 V and 0.4 ms, delivered at 100 Hz to the L4 or L5 dorsal root entering the slice. These are optimal parameters to induce substance P release (Adelson et al., 2009) . Electrical stimulation was generated by a Master-8 stimulator and an Iso-Flex stimulus isolating unit in constant voltage mode (AMP Instruments, Jerusalem, Israel). Slices were superfused in a custommade chamber at 3e6 ml/min with aCSF at 35 C. The dorsal root was drawn into a side compartment containing a bipolar platinum stimulation electrode (0.5 mm wire diameter, 1 mm separation) through a hole in a movable partition sealed with vacuum grease, and placed on top of the wires. Contact between the root and the electrode wires was monitored with a stereomicroscope. The electrode compartment was emptied of aCSF and filled with mineral oil. This arrangement ensured that the electrical pulses consistently stimulated the root and could not stimulate the dorsal horn.
At the end of the experiment, slices were fixed by immersion in ice-cold fixative (4% paraformaldehyde, 0.18% picric acid).
Intrathecal injections
To deliver drugs to the lumbar spinal cord, rats were surgically implanted with chronic intrathecal catheters inserted between the L5 and L6 lumbar vertebrae (Chen and Marvizon, 2009; Storkson et al., 1996) . Rats (2e4 months old) were anesthetized with isoflurane (2e4% in oxygen, Halocarbon Laboratories, River Edge, NJ) and kept under anesthesia on a metal platform maintained at 35 C by a feedback device. The skin and muscle were cut to expose vertebrae L5 and L6. A 20G needle was inserted between the L5 and L6 vertebrae to puncture the dura mater, which was inferred from a flick of the tail or paw and the backflow of spinal fluid. The needle was removed and the catheter (20 mm of PE-5 tube heat-fused to 150 mm of PE-10 tube) was inserted into the subdural space and pushed rostrally. The PE-10 catheter was then tunneled under the skin and externalized over the head. The skin was sutured, and the catheter was flushed with 10 ml saline and sealed. Rats were given an antibiotic (enrofloxacin) and an analgesic (carprofen) twice daily for 3 days after surgery. Rats were housed separately and used for the experiment 5e7 days after surgery. The presence of motor weakness or signs of paresis was established as criterion for immediate euthanasia of the rat, but this did not occur in any of the rats in this study.
Intrathecal injection volume was 10 ml of injectate plus 10 ml saline flush (Jensen and Yaksh, 1984; Kondo et al., 2005) . This volume leads to the distribution of the injectate over most of the spinal cord, but not into the brain (Chen et al., 2007; Yaksh and Rudy, 1976) . Solutions were preloaded, in reverse order of administration, into a tube (PE-10), and delivered with a 50 ml Hamilton syringe within 1 min. The position of the catheter was examined postmortem. We established the following exclusion criteria: 1) loss of the catheter, 2) termination of the catheter inside the spinal cord, and 3) occlusion of the catheter tip.
Characterization of the NK1R antiserum
The NK1R antiserum was either 94168 from CURE: Digestive Diseases Research Center (University of California Los Angeles) or AB5060 purchased from EDM Millipore (Billerica, MA). Both antiserums were generated in rabbits. Immunogens were peptides at the C-terminus of the rat NK1R, amino acids 393e407 for 94168 and amino acids 385e407 for AB5060. Antiserum 94168 labeled cells transfected with rat NK1R (but not non-transfected cells); its staining was eliminated by preadsorption with the immunizing peptide, and it yielded a single band in Western blots corresponding to a molecular weight of 100 kDa (Grady et al., 1996) . Both antiserums produced the same labeling pattern of the rat dorsal horn, which was identical to that observed in numerous previous studies using these and other NK1R antibodies (Adelson et al., 2009; Allen et al., 1997; Kondo et al., 2005; Mantyh et al., 1995) .
Immunohistochemistry
Rats were euthanized with pentobarbital (100 mg/kg) and fixed by aortic perfusion of 100 ml phosphate buffer (0.1 M sodium phosphate, pH 7.4) containing 0.01% heparin, followed by 400 ml of ice-cold fixative (4% paraformaldehyde, 0.18% picric acid in phosphate buffer). A segment of the lumbar spinal cord (L4-L6) was post-fixed, cryoprotected, frozen and sectioned at 25 mm in the coronal plane using a cryostat (Chen et al., 2007; Lao et al., 2008) . Spinal cord slices were fixed and processed similarly (Adelson et al., 2009; Lao and Marvizon, 2005; Lao et al., 2003; Marvizon et al., 2003a) . Sections were washed four times and then incubated overnight at room temperature with the NK1R antiserum diluted 1:3000 in phosphate-buffered saline containing 0.3% Triton X-100, 0.001% thimerosal and 5% normal goat serum (Jackson ImmunoResearch Laboratories, West Grove, PA). After three washes, the secondary antibody (1:2000, Alexa Fluor 488 goat anti-rabbit, Molecular Probes-Invitrogen, Eugene, OR) was applied at for 2 h at room temperature. Sections were washed four more times, mounted on glass slides, and coverslipped with Prolong Gold (Molecular Probes-Invitrogen).
Quantification of NK1R internalization
We used NK1R internalization as a measure in situ of substance P release. This method has higher sensitivity than immunoassay (Marvizon et al., 2003a) , can be used non-invasively in vivo (Honore et al., 1999; Mantyh et al., 1995) , allows the spatial location of substance P release (Abbadie et al., 1997; Hughes et al., 2007) and measures substance P release at the physiologically relevant concentrations that activate NK1Rs (Trafton et al., 1999) .
The amount of NK1R internalization was quantified using a standard method (Mantyh et al., 1995) with minor modifications (Adelson et al., 2009 ). NK1R neurons in lamina I were visually counted while classifying them as with or without internalization, using a Zeiss Axio-Imager A1 (Carl Zeiss, Inc., Thornwood, NY) fluorescence microscope with a 63x (1.40 numerical aperture) objective. The criterion for having internalization was the presence in the neuronal soma of ten or more NK1R endosomes, defined as a small region of bright staining separated from the cell surface. The person counting the neurons was blinded to the treatment. Four sections per spinal segment or slice were used, counting all lamina I NK1R neurons in each section. Results were expressed as the percentage of the NK1R neurons in lamina I with NK1R internalization.
Confocal microscopy
Confocal images were acquired using a Zeiss LSM 710 confocal microscope (Carl Zeiss, Inc., Thornwood, NY), with objectives of 20x (numerical aperture 0.8) and 63x oil (numerical aperture 1.4). Excitation light for the Alexa Fluor 488 fluorophore (emission peak 519 nm) was provided by the 488 nm line of an argon laser. The emission window was 500e560 nm. The pinhole was 1.0 Airy unit: 31.5 mm for the 20x objective and 50.7 mm for the 63x objective, as determined by the confocal microscope software. Images were acquired in grayscale as confocal stacks of sections of 1024 Â 1024 pixels. Each section was averaged 2 times to reduce noise. The separation between confocal sections was 0.85 mm for the 20x objective and 0.38 mm for the 63x objective, as determined by the confocal microscope software using the Nyquist formula. Photomultiplier gain and offset were adjusted before acquiring each confocal stack to avoid pixel saturation.
Image processing
Images of the entire dorsal horn obtained with the 20x objective were used to show the location of each of the neurons imaged with the 63x objective. The program Imaris 6.1.5 (x64, Bitplane AG, Zurich, Switzerland) was used to crop the images in three dimensions. Images at 20x were cropped into the 10 brightest optical sections. Often, images of several NK1R neurons were acquired in a single confocal stack, in which case Imaris was used to crop each cell out of the stack into 4e6 optical sections through the middle of the cell. After cropping, a two-dimension projection picture was generated in Imaris and imported into Adobe Photoshop 5.5 (Adobe Systems Inc., Mountain View, CA), which was used to adjust the gamma, compose the multi-panel figures and to add text and arrows.
Dorsal root ganglion (DRG) neuron culture
Primary cultures of DRG neurons from spinal levels T12-S2 were prepared as previously described with minor modifications (Li et al., 2006) . Neurons were plated on coverslips coated with Matrigel (BD Biosciences, San Jose, CA) in Neurobasal media containing B-27 supplement, 5 ng/ml nerve growth factor (all from Life Technologies, Grand Island, NY), 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA) and 200 mM ketamine (Sigma). Ketamine in the culture medium is necessary to preserve NMDA receptor function in cultured DRG neurons (Chen et al., 2014 ] i ) measurement DRG neurons were used 2e3 days after plating. Neurons were loaded for 1 h at 37 C on coverslips with 5 mM Fura-2 AM (Life Technologies) in Neurobasal media supplemented as described above, then washed and incubated for 30 min in Mg 2þ -free Hank's buffer containing 10 mM Hepes, pH 7.2, 5 mM glucose, 1.2 mM CaCl 2 . During the last 15 min, the incubation buffer was supplemented 20 ng/ml BDNF with or without 1 mM DAMGO. In some experiments, the irreversible Cav2 channel blocker CTX GVIA
(1 mM) was added to the neurons during the 1-h incubation with Fura-2. Coverslips were mounted in an experimental chamber (volume 0.5 ml) and perfused (0.5 ml/min) with the same buffer. The chamber was placed on the stage of an inverted microscope (Axio Observer.A1) outfitted with a 40x objective and a digital camera (AxioCam MRm) and operated with associated software (AxioVision, Carl Zeiss, Thornwood, NY). Ratio images (340 nm/ 380 nm) were obtained at 1 s intervals, and the average ratio values from each cell were stored for offline analysis. Neurons were stimulated by rapid addition of NMDA and glycine to a final concentration of 250 mM and 10 mM, respectively. KCl (50 mM final)
was added at the end of the experiment a means to verify viable neurons. Responses were evaluated as the change in the 340 nm/ 380 nm ratio from the initial baseline value to the peak value. In a subset of cells, initial resting [Ca 2þ ] i was estimated to be 91 ± 15 nM (n ¼ 20) using the method of Williams and Fay (1990) .
Experimental design and statistical analysis
Data were analyzed using Prism 7.03 (GraphPad Software, San Diego, CA). Statistical significance was set at 0.05. Data points and error bars indicate mean and standard error, except for [Ca 2þ ] i measures where they show the median response and the interquartile range.
A power analysis (PASS software) of previous NK1R internalization data revealed that a sample size of 4 provides 81% power in a two-sample t-test with 0.05 two-sided significance to detect effect sizes of 2.27 (in slices) or 2.57 (in vivo).
Experiments in spinal cord slices: Data were collected in weekly experiments of 12e24 slices prepared from 2 to 8 rats. Typically, 3e8 slices were obtained per rat. The number of slices for each data point is indicated in the figures. Replicates in each data point are from slices from more than one rat, so the statistical error represents both inter-slice and inter-animal variability. We set the target sample size at n ¼ 6 per group, with the following exceptions. In concentration-response and time course experiments we used a minimum of 3 slices per data point because statistical significance depends on the sample size of the whole curve. Control data include a large number of slices because separate controls were included in each weekly experiment to assess consistency, and controls were later aggregated for the whole experiment. Likewise, a larger sample size resulted when the same data were collected in different experiments and then aggregated. In some critical experiments with atypical results, the sample size was increased to rule out the presence of outliers or experimental mistakes. Statistical analyses consisted of one-way ANOVA followed by HolmSidak's post-hoc tests, except that non-linear regression analyses were used in the following experiments. Concentration-response data were fitted by a sigmoidal dose-response function:
, where X is the concentration of drug and IC 50 is the concentration of drug that produces half of the effect. The Hill coefficient was assumed to be 1.0. Baseline measures (zero concentration of drug) were included in the non-linear regression by assigning them a concentration value three log units lower than the lowest concentration of drug. Parameter constraints were: 0% < top <100%, 0% < bottom. The statistical error of the IC 50 is expressed as asymmetrical 95% confidence intervals (CI). Data from multiple concentration-response curves were fitted simultaneously and Akaike's Information Criterion was used to test whether the two curves had the same or different parameter values. Concentration-responses of an agonist in the absence and presence of an antagonist were fitted using the Gaddum-Schild model (Colquhoun, 2007) to calculate the IC 50 of the agonist and the K B of the antagonist. In this case, the top and bottom parameters were constrained to be the same for both curves. Time course data were fitted by non-linear regression to a one phase decay function: Y ¼ (Y 0 -plateau) * exp(-K *X) þ plateau, where K is the rate constant, Y 0 is the value at time 0 and "plateau" is the maximum value. Half-life was calculated as ln(2)/K.
Experiments in vivo: The target sample size was n ¼ 8, but some rats were eliminated from data collection due to death or misplacement of the intrathecal catheter revealed by post-mortem examination. Rats were randomly assigned to treatment. The investigator quantifying the NK1R internalization data was blinded to treatment. Statistical analyses consisted of one-way ANOVA followed by Holm-Sidak's post-hoc tests.
Experiments in cell cultures: Measures of [Ca 2þ ] i presented a large variability due to cell heterogeneity, so they required using a large number of cells. Separate controls were used for batches of cells prepared under slightly different conditions. Results were analyzed with the Mann-Whitney test due to the non-Gaussian distribution of the [Ca 2þ ] i data. Lines in the figure show the median response and error bars show the interquartile range.
Results and discussion

MOR inhibition of NMDA-induced substance P release
Our first objective was to determine whether MORs inhibit substance P release in the spinal cord induced by NMDA receptor activation, which was accomplished by incubating rat spinal cord slices for 2 min with 10 mM NMDA and 10 mM D-serine (D-Ser). MOR agonists and antagonists were added to the slices during a 60 min incubation prior to the 2 min incubation with NMDA. All incubations were done at 35 C in oxygenated and buffered aCSF. As we previously reported (Chen et al., , 2014 , NMDA induced NK1R internalization in about 50% of the NK1R neurons in lamina I ( Fig. 1 A, 'control' ). The MOR agonists morphine, endomorphin-2 and DAMGO (all 1 mM) reduced NMDA-induced NK1R internalization to control levels ( Fig. 1 A) , showing that MORs are able to abolish NMDA-induced substance P release. The inhibition by DAMGO was eliminated by the MOR antagonists naloxone, naltrexone or CTAP (all 10 mM, Fig. 1 A) , showing that it has the expected pharmacological profile of MORs. ANOVA of data in Fig. 1 A: p < 0.0001, F 9,58 ¼ 51.25.
Unexpectedly, DAMGO plus naltrexone produced a small but statistically significant increase of NMDA-induced NK1R internalization, and a trend in that direction was observed with naltrexone alone. Since naltrexone is an inverse agonist of MORs (Kenakin, 2001) , this may reflect the presence of some MOR constitutive activity (Connor and Traynor, 2010; Walwyn et al., 2016) .
To obtain further evidence of the involvement of MORs, we performed a Gaddum-Schild analysis by obtaining concentrationresponse curves for DAMGO in the absence and presence of the MOR-selective antagonist CTAP (10 mM). DAMGO produced a concentration-dependent inhibition of NMDA-induced substance P release with an IC 50 of 10 nM (Fig. 1 B) , similar to its potency to induce MOR internalization (30 nM) (Marvizon et al., 1999) , to inhibit adenylyl cyclase (5e18 nM) (Keith et al., 1998; Yabaluri and Medzihradsky, 1997) and to increase [g-35 S]GTP binding (28 nM) (Yabaluri and Medzihradsky, 1997) . CTAP produced a marked rightshift of the concentration-response curve, resulting in an equilibrium dissociation constant (K B ) for CTAP of 136 nM in the GaddumSchild analysis. The corresponding pA2 value was 6.87 (95% CI ¼ 6.40e7.36), similar with the pA2 reported for CTAP in guinea pig ileum: pA2 ¼ 7.36 (95% CI ¼ 6.83e7.78) (Kramer et al., 1989) . The inhibition produced by DAMGO was complete, since the 'bottom' parameter of its concentration-response curve, 17 ± 3%, was similar to control NK1R internalization values in the absence of NMDA, 12 ± 1% ("no NMDA", Fig. 1 A) .
Time course of the inhibition by DAMGO of NMDA-induced substance P release
In the previous experiments spinal cord slices were incubated with MORs agonists for 60 min before the short (2 min) incubation with NMDA and D-Ser that evoked substance P release. In this experiment we studied the effect of the incubation time with DAMGO. First, we determined whether 1 mM DAMGO co-applied with NMDA and D-Ser to the slices for 2 min decreased NMDAinduced NK1R internalization. In this case DAMGO produced no inhibition (Fig. 2 , "0 min") compared with the effect of NMDA without DAMGO ("none"): p ¼ 0.317, Holm-Sidak's post-hoc test of one-way ANOVA (global p < 0.0001, F 6,41 ¼ 22). Second, we preincubated spinal cord slices with 1 mM DAMGO for various times prior to the 2 min incubation with NMDA and D-Ser (10 mM). As shown in Fig. 2 , the inhibition by DAMGO was nearly complete at 15 min. Fitting of a one-phase decay function to these data yielded a time constant K ¼ 0.18 ± 0.08 min
À1
, corresponding to a half-life of 3.8 min (95% CI 1.1 min -11.5 min).
MORs inhibit NMDA-induced substance P release in vivo
Next, we studied whether MORs also inhibit substance P release induced by intrathecal NMDA in vivo. Whereas in slices NMDA readily evokes substance P release, in vivo NMDA does not consistently elicit substance P release (Chen et al., 2014; Nazarian et al., 2008) . However, intrathecal NMDA evokes substance P release after nerve injury or intrathecal BDNF (Chen et al., 2014) . This substance P release is mediated by NMDA receptors present in primary afferents because it disappeared in mice with selective NR1 subunit knockdown in nociceptive afferents (Chen et al., 2014) . Since the effect of BDNF lasts more than 4 h, we devised a protocol consisting in three sequential intrathecal injections: 1) at 0 h, saline or BDNF (0.3 mg); 2) at 3 h, saline or DAMGO (3 nmol); 3) at 4 h, NMDA þ DSer (10 nmol each). Rats were killed and fixed 10 min after the third injection. Intrathecal injections were delivered through catheters terminating at the L4-L5 spinal cord segments and NK1R internalization was measured in segment L4. Consistent with our previous results (Chen et al., 2014) , after two injections of saline NMDA produced little NK1R internalization, except in three out of eight rats (Fig. 3, "NMDA") . Examples of lamina 1 neurons with NK1R surface staining in a rat from this group are shown in Fig. 4 A. Without BDNF, intrathecal DAMGO did not affect NMDA-induced NK1R internalization, except that outliers with high NK1R internalization were no longer observed (Fig. 3) . Intrathecal BDNF resulted in a significant increase in NMDA-induced NK1R internalization (Fig. 3 , "BDNF þ NMDA"). Examples of five lamina 1 neurons with NK1R internalization in a rat injected with BDNF and NMDA are shown in Fig. 4 B. When injected 3 h after BDNF, DAMGO significantly inhibited NMDA-induced NK1R internalization (Fig. 3 , one-way ANOVA: p ¼ 0.0011, F 3,25 ¼ 7.33, Holm-Sidak's post-hoc tests are indicated in the figure) . Examples of lamina 1 neurons with NK1R surface staining after DAMGO are shown in Fig. 4 C. Therefore, in vivo MORs inhibit substance P release induced by intrathecal NMDA only after priming with BDNF.
Contribution of Cav channels to NMDA-induced substance P release
Once we established that MORs inhibit NMDA-receptor induced substance P release, we investigated the mechanisms by which MORs may interact with these NMDA receptors. The substance P released in these experiments is from primary afferents because it disappears after depleting C-fibers of substance P by incubating the slices with capsaicin . Likewise, the NMDA receptors that induce the substance P release are present in primary afferents because NMDA-induced substance P release decreased considerably in mice with a selective deletion of NMDA receptors in nociceptive primary afferents (Chen et al., 2014) . NMDA-induced substance P release was not affected when firing of action potentials was blocked by lidocaine , indicating that the NMDA receptors are present at the presynaptic terminals.
NMDA receptors may induce substance P release by two mechanisms: 1) direct Ca 2þ entry through NMDA receptors, 2) Ca 2þ entry through Cav channels activated by the depolarization they produce. Since MORs inhibit Cav2 channels in primary afferent (Moises et al., 1994; Raingo et al., 2007; Rusin and Moises, 1998; Strock and Diverse-Pierluissi, 2004) , the second mechanism could explain their inhibition of NMDA receptor-induced substance P release. To evaluate the relative contribution of these two mechanisms, we determined whether NMDA-induced substance P release can be inhibited by the Cav channel blockers CTX MVIIC and CTX GVIA. CTX MVIIC blocks Cav2.2 (N type) channels with an IC 50 18 nM and Cav2.1 (P/Q type) channels with an IC 50 of 50 nM (McDonough et al., 1996; Rusin and Moises, 1995) . CTX GVIA blocks Cav2.2 channels selectively and irreversibly (Hannon and Atchison, 2013; Keith et al., 1989; Moises, 1995, 1998) . The Cav channels that are present in primary afferent terminals and are inhibited by MORs are Cav2.2 and Cav2.1 (Rusin and Moises, 1995) .
To study the effect of CTXs on NMDA-induced substance P release, slices were incubated for 60 min with different concentrations of CTX MVIIC or CTX GVIA, and then for 2 min with 10 mM NMDA and D-Ser. The IC 50 s for CTX MVIIC and CTX GVIA were 117 nM and 374 nM, respectively (Table 1) . Both CTXs produced a partial inhibition of the evoked NK1R internalization (Fig. 5, Table 1 ), to 34 ± 4% for CTX MVIIC and to 34 ± 6% for CTX GVIA, well above basal NK1R internalization in the absence of NMDA, which was 12 ± 1% (dotted lines in Fig. 5 ).
As a positive control, we studied the inhibition by CTXs of substance P release induced by electrical stimulation of the dorsal root, which induces firing of action potentials in primary afferents (Adelson et al., 2009) leading to the opening of Cav channels in their central terminals. This electrical stimulation induced about the same amount of NK1R internalization as NMDA ( Fig. 5 ; Table 1 , top parameters). CTX MVIIC was applied to the slices for 2 min prior and during electrical stimulation. The concentration-response curve for CTX MVIIC using this stimulus was very similar to its concentration-response when NMDA was used as stimulus (Fig. 5  A) . The inhibition was also partial, with a maximal inhibition ('bottom') of 28 ± 7% (Table 1) , with a 65% probability of being the same as with NMDA (Akaike's Information Criterion from global fitting of both curves). The IC 50 was 267 nM (Table 1) , with a 70% probability of being the same as with NMDA (Akaike's Information Criterion). Therefore, CTX MVIIC had the same potency and efficacy to inhibit substance P release evoked by NMDA or by dorsal root stimulation, indicating that Cav2 channels are similarly involved in both processes.
Since the Cav2 blockers CTX MVIIC and CTX GVIA only partially inhibited NMDA-induced substance P release, both routes of Ca 2þ entry seem to be involved. It is unlikely that the effect of the CTXs was due to direct inhibition of the NMDA receptors because CTX MVIIC inhibited NMDA-induced substance P release with the same potency as that elicited by electrical stimulation of the dorsal root. The later involves primary afferent firing, so it is likely to be mediated by Cav channel opening.
When using dorsal root stimulation, the concentration-response curve for CTX GVIA was anomalous (Fig. 5 B) . Given its slow association kinetics (Hannon and Atchison, 2013) , CTX GVIA was applied to the slices for 60 min and then superfused during root stimulation. The resulting concentration-response was V-shaped. Increasing the sample size of the data points showed that this was not due to the presence of outliers. Fitting to a V-shaped curve was not attempted, since this would be hard to interpret. It is possible that the V-shaped response is due to nonselective effects at the higher doses of CTX GVIA, such as effects on other channels Parameters obtained from non-linear regression fitting of data in Fig. 5 to a doseresponse function. The Hill coefficient was assumed to be 1.0. 95% CI: 95% confidence interval (profile likelihood).
activated by dorsal root stimulation. There is evidence that high frequency electrical stimulation leads to anomalous binding of CTX GVIA to Cav2 channels, resulting in partial inhibition of neurotransmitter release (Smith and Cunnane, 1998) .
TRPV1-induced substance P release is not inhibited by MORs
Capsaicin is another powerful stimulus to evoke substance P release from primary afferents (Aimone and Yaksh, 1989; Lao et al., 2003; Marvizon et al., 2003a) . This effect of capsaicin is mediated by the opening of TRPV1 channels, since it was blocked by the TRPV1 antagonist capsazepine (Lao et al., 2003) . Since TRPV1 channels directly produce a strong influx of Ca 2þ , they may bypass the inhibition of Cav channels by MORs (Moises et al., 1994; Raingo et al., 2007; Rusin and Moises, 1995) . To investigate this possibility, we investigated whether MORs inhibit capsaicin-induced substance P release. As in previous experiments, spinal cord slices were incubated for 60 min with the MOR agonist DAMGO (100 nM) and then for 2 min with capsaicin. Capsaicin at 1 mM elicited maximal NK1R internalization, which was not affected by DAMGO (Fig. 6 A) . To determine whether DAMGO was able to inhibit sub-maximal substance P induced by capsaicin, we repeated the experiment lowering the concentration of capsaicin to 0.3 mM, which is near its EC 50 to induce NK1R internalization (0.37 mM) (Marvizon et al., 2003a) . This time 0.3 mM capsaicin produced 75% NK1R internalization and this was still unaffected by DAMGO (Fig. 6 B) .
If capsaicin induces substance P release by allowing Ca 2þ entry through TRPV1 channels, then it would not require Ca 2þ entry through Cav channels. If this is true, then Cav channel blockers would not affect capsaicin-induced substance P release. Indeed, the Cav2 channel blockers CTX MVIIC and CTX GVIA (1 mM) did not inhibit NK1R internalization induced by 1 mM capsaicin (Fig. 6 A) . When the concentration of capsaicin was lowered to 0.3 mM, CTX MVIIC showed a trend to inhibit NK1R internalization, but this effect was not statistically significant (p ¼ 0.27, Holm-Sidak's posthoc test). Therefore, MORs do not inhibit capsaicin-induced substance P release because Ca 2þ entry through TRVP1 channels bypasses MOR inactivation of Cav2 channels. These results appear to contradict early reports in which MOR inhibition of substance P release was demonstrated using capsaicin as the stimulus (Aimone and Yaksh, 1989 ). However, we have shown (Lao et al., 2003 ) that when capsaicin is applied to the dorsal root to open TRPV1 channels away from the presynaptic terminal, or when low concentrations of capsaicin are used, substance P release does require Cav2 channels and can be inhibited by the GABA B receptor agonist baclofen. Like DAMGO, baclofen did not inhibit substance P release when higher concentrations of capsaicin were used (Lao et al., 2003) . Therefore, it is likely that the intrathecal superfusion with capsaicin used by Aimone and Yaksh opened a small number of TRPV1 channels, so that substance P release required opening of Cav2 channels in addition of TRPV1 channels.
NMDA-induced increases in [Ca 2þ ] i in cultured DRG neurons
To study Ca 2þ entry through NMDA receptors we measured increases in [Ca 2þ ] i induced by NMDA in cultured DRG neurons (Li et al., 2004; McRoberts et al., 2001 McRoberts et al., , 2007 . Rat DRG neurons were isolated and cultured for 2 days in media containing 200 mM ketamine in order to preserve NMDA receptor function (Chen et al., 2014) . The DRG neurons were loaded for 1 h with Fura-2 AM (5 mM) and preincubated for 15 min with BDNF (20 ng/ml) to boost NMDA receptor function (Chen et al., 2014) . Then [Ca 2þ ] i was measured with a fluorescence microscope while the cells were superfused with medium. Addition of NMDA (250 mM) plus glycine (10 mM) produced [Ca 2þ ] i increases in some of the neurons, which varied from slow-developing (Fig. 7 A) to small and rapid (Fig. 7 B,  C) . [Ca 2þ ] i returned to baseline upon washout (Fig. 7) . These experiments were done in small to medium sized DRG neurons. Large DRG neurons generally did not respond to NMDA with detectable increases in [Ca 2þ ] i . Addition of 1 mM DAMGO during the preincubation with BDNF resulted in smaller increases in [Ca 2þ ] i produced by NMDA þ glycine (Fig. 7DeF) . Fig. 8 the peak response by 56% (Fig. 8 A; Mann-Whitney test p ¼ 0.012). This finding is consistent with an inhibition of NMDA receptors by MORs.
To determine whether the increase in [Ca 2þ ] i produced by NMDA þ glycine could be due in part to Ca 2þ entry through Cav2 channels, the Cav2.2 channel blocker CTX GVIA (1 mM) was added during the 1 h incubation of the DRG neurons with Fura-2. CTX GVIA did not affect the responses to NMDA þ glycine (Fig. 8 B, p ¼ 0.7), indicating that the Ca 2þ entry produced by NMDA was through the NMDA receptors themselves and not through Cav2 channels. One possibility is that Cav2 channels are present in the presynaptic terminals but not in the cell bodies of DRG neurons. As a positive control, at the end of the experiment we induced Ca 2þ entry in the DRG neurons by depolarizing them with 50 mM KCl. This produced rapid and large increases in [Ca 2þ ] i in all DRG neurons. Incubating these neurons for 1 h with 1 mM CTX GVIA decreased the KCl-evoked raises in [Ca 2þ ] i (Fig. 8 C, ] i responses in DRG neurons. A. Cultured DRG neurons were loaded for 1 h with 5 mM Fura-2 AM and then incubated for 15 min with 20 ng/ml BDNF with or without 1 mM DAMGO. Responses were evoked by rapid infusion of 250 mM NMDA þ 10 mM glycine. B. DRG neurons were loaded for 1 h with Fura-2 AM without (control) or with 1 mM CTX GVIA (CTX), and then incubated with BDNF as above before stimulation with 250 mM NMDA þ 10 mM glycine. C. Neurons loaded with Fura-2 AM for 1 h with or without CTX GVIA were stimulated with 50 mM KCl to induce the opening of Cav channels. Bars show the median response and the interquartile range. A Mann-Whitney test was used to obtain the p values given in each panel.
primary afferents by a mechanism other than inactivation of Cav2 channels.
2.7. Most NMDA receptors that induce substance P release contain the NR2B subunit Besides inactivating Cav2 channels, MORs also inhibit adenylyl cyclase (AC). Protein kinase A (PKA), which is activated by cAMP produced by AC, phosphorylates NMDA receptors at Ser 1166 of their NR2B subunit, and this is required for NMDA receptor function (Lau et al., 2009; Murphy et al., 2014) . Therefore, inhibition of AC could provide an additional pathway by which MORs inhibit NMDA receptors in primary afferent terminals. Indeed, the NR2B subunit is widely expressed in DRG neurons (Marvizon et al., 2002) . To confirm that the NMDA receptors that induce substance P release have the NR2B subunit we assessed whether they are inhibited with high potency by the NR2B-selective antagonist ifenprodil. Spinal cord slices were incubated with different concentrations of ifenprodil for 45 min and then with NMDA and D-Ser for 2 min. The resulting concentration-response curve had an IC 50 of 1.6 nM (95% CI ¼ 0.7e3.6 nM, Fig. 9 ), a potency higher than that reported for ifenprodil to inhibit currents through NR1a/NR2B NMDA receptors in Xenopus oocytes, 340 nM (Williams, 1993) , or the K D for ifenprodil binding to rat brain membranes, 25 nM (Grimwood et al., 2000) . This shows that the NMDA receptors that induce substance P release have the NR2B subunit. Maximal inhibition by ifenprodil ('bottom') was 26 ± 2% NK1R internalization, whereas NK1R internalization in the absence of NMDA was 12 ± 1% (dotted line in Fig. 9 ). This partial inhibition suggests that a small fraction of the substance P release may be induced by NMDA receptors without the NR2B subunit.
2.8. The AC/PKA pathway facilitates NMDA receptor-induced substance P release
One of the main signaling mechanisms of MORs is inhibition of AC (Childers, 1991; Piros et al., 1996) . NMDA receptors containing the NR2B subunit are sensitive to AC inhibition because they require NR2B phosphorylation at Ser 1166 by PKA (Murphy et al., 2014) . The NR2B subunit is expressed in all types of DRG neurons (Marvizon et al., 2002) and is involved in the pro-nociceptive effects of NMDA receptors (Tan et al., 2005) . The potent inhibition produced by ifenprodil demonstrates that most NMDA receptors that induce substance P release do have the NR2B subunit, so their function probably requires PKA phosphorylation.
To explore this possibility, we first studied the effects of activating AC or PKA on substance P release. To activate AC, spinal cord slices were incubated for 60 min with 10 mM forskolin. To directly activate PKA, slices were incubated for 60 min with the cellpermeable cAMP analog 8-Br-cAMP (0.5 mM) (Brown et al., 2000; Yang et al., 2005) . Surprisingly, both compounds elicited an amount of NK1R internalization greater than NMDA þ D-Ser, with 8-Br-cAMP producing the larger effect (Fig. 10 A) . Addition of the NMDA receptor blocker MK-801 (10 mM) during the incubation with forskolin or 8-Br-cAMP substantially decreased their effect on substance P release, although not to control levels. This shows that the induction of substance P release by forskolin and 8-Br-cAMP is mediated by NMDA receptors. Likewise, addition of the MOR agonist DAMGO (1 mM) during the incubation with forskolin or 8-Br-cAMP markedly decreased the evoked substance P release (Fig. 10 A) , but not to control levels. Since activation of PKA by 8-BrcAMP is downstream of MOR inhibition of AC, this probably reflects MOR inactivation of Cav2 channels. These results indicate that in basal conditions NMDA receptors in primary afferent terminals are only partly phosphorylated at Ser 1166 by PKA, and that their complete phosphorylation in the presence of forskolin or 8-Br-cAMP enables their activation by background amounts of glutamate and glycine. Hence, activation of the AC-PKA pathway in primary afferents would result in a large increase in NMDA receptor function, leading to hyperalgesia. Next, we studied whether the NMDA receptors that induce substance P release depend on the activation of AC and PKA, by using the AC inhibitor SQ22536 and the PKA inhibitors KT5720 and PKI 14e22. NK1R internalization induced by applying NMDA þ DSer (10 mM) to spinal cord slices was decreased by the AC inhibitor SQ22536 at 100 mM, but not at 10 mM (Fig. 10 B) . SQ22536 is normally used at 50 mM or 100 mM (Chang et al., 2010; Evans et al., 2001; Shi and Bunney, 1992) . NMDA-induced NK1R internalization was also decreased by the PKA inhibitors KT 5720 (10 mM) and PKI 14e22 myristolated (10 mM). These results show that complete elimination of PKA phosphorylation of these NMDA receptors at Ser 1166 suppresses their activation even by saturating concentrations of NMDA and D-Ser. Therefore, the well-established inhibition of AC by MORs would decrease NMDA receptor-induced substance P release.
MORs inhibit the CTX-insensitive component of substance P release
CTX MVIIC and CTX GVIA only blocked part of the NMDAinduced substance P release (to 34%, compared to 12% basal NK1R internalization, Fig. 5 , Table 1 ) while MOR agonists completely abolished it (Fig. 1) . This suggests that MORs are able to inhibit NMDA-induced substance P by mechanisms other than inactivation of Cav2 channels. To confirm this, we determined whether 1 mM DAMGO produced an additional inhibition of substance P release in the presence of maximal concentrations (1 mM) of CTX MVIIC (Fig. 10 C) or CTX GVIA (Fig. 10 D) . As usual, spinal cord slices were incubated for 60 min with CTX and DAMGO and then with for 2 min NMDA and D-Ser. Indeed, DAMGO produced a significant decrease in the presence of either CTX. Since this additional inhibition cannot be attributed to Cav2 inactivation, MOR inhibition of NMDA receptor-induced substance P release has to be mediated by an additional mechanism.
Then we explored whether the AC inhibitor SQ22536 (100 mM) or the PKA inhibitor KT5720 (10 mM) could similarly inhibit the CTX-insensitive component of substance P release. We found that these two inhibitors did not produce any further inhibition in the presence of CTXs (Fig. 10 C, D) . However, unlike DAMGO, these two inhibitors did not completely abolish NMDA-induced NK1R internalization (Fig. 10 B) . This, together with the small inhibition produced by DAMGO in the presence of CTX, make the interpretation of these results difficult. One possibility is that the MOR inhibition additional to Cav channel inactivation is not due to AC inhibition. Another possibility is that PKA phosphorylates the same population of NMDA receptors that trigger the opening of Cav2 channels. This implies that there is a third mechanism of MOR inhibition of NMDA receptor-induced substance P release.
MOR inhibition is not mediated by GIRK channels
One of such mechanisms could be the opening of GIRK channels (Marker et al., 2005; Schneider et al., 1998) , which would produce hyperpolarization and thus increase the Mg 2þ blockade of NMDA receptors. GIRK channels are present in primary afferent neurons of rats and humans (but not mice), where they mediate the analgesia produced by peripherally-restricted opiates (Nockemann et al., 2013) . This hypothesis predicts that DAMGO inhibition of NMDAinduced substance P release would be reversed by the GIRK inhibitor tertiapin-Q (Jin et al., 1999) . Therefore, we incubated spinal cord slices for 60 min with 1 mM DAMGO, 100 nM tertiapin Q or DAMGO þ tertiapin Q. Unexpectedly, tertiapin Q alone produced a small but significant inhibition of NMDA-induced NK1R internalization (Fig. 10 E) . In any case, tertiapin Q did not affect the inhibition by DAMGO: results in the presence of DAMGO alone and DAMGO þ tertiapin Q were not statistically different (p ¼ 0.108, Holm-Sidak's post-hoc test). Therefore, GIRK opening does not seem to mediate the MOR inhibition of NMDA receptor-induced substance P release. Consistent with our results, MOR inhibition of Ad-and C-fiber-evoked EPSCs in rat spinal cord slices was not affected by the K þ channels blockers Ba 2þ and Cs þ (Heinke et al., Fig. 10 . Involvement of AC, PKA and PKC on substance P release. A: Spinal cord slices were incubated for 60 min with 10 mM forskolin, 0.5 mM 8-Br-cAMP, or nothing (control). MK-801 (10 mM) or DAMGO (1 mM) were added at the same time as forskolin or 8-Br-cAMP. B-I: Substance P release was induced by incubating spinal cord slices for 2 min with 10 mM NMDA and 10 mM D-Ser. Before that, the slices were incubated for 60 min with the other compounds indicated. Compounds listed inside the panels above "þ NMDA" were applied to all of the slices in that panel, and were: 1 mM CTX MVIIC (C), 1 mM CTX GVIA (D), 20 ng/ml BDNF (H), and 10 mM BVT948 (I). In these panels, 'control' refers to slices incubated with these compounds followed by NMDA þ D-Ser. Other compounds were: 10 mM chelerythrine (PKC inhibitor), 1 mM DAMGO, 10 mM KT5720 (PKA inhibitor), 10 mM PKI 14e22 myristolated (PKA inhibitor), 1 mM phorbol 12-myristate 13-acetate (PMA, PKC activator), 1 mM Ro-32-0432 (PKC inhibitor), 10 mM or 100 mM SQ 22536 (AC inhibitor), 100 nM tertiapin Q (GIRK inhibitor), and 1 mM TPPB (PKC activator Studies in the periaqueductal gray by the group of Javier Garz on Rodríguez-Muñoz et al., 2008 2012) have shown that MORs are able to physically associate with NMDA receptors at postsynaptic sites. This promotes the analgesic effect of morphine by inhibiting the NMDA receptors. This physical association is disrupted by PKC phosphorylation of either the MOR or the NR1 subunit of the NMDA receptor, in both cases leading to a decrease in MOR analgesia. To determine whether this mechanism mediates MOR inhibition of NMDA receptors in primary afferent terminals, we studied the effect of PKC inhibitors and activators on the inhibition by DAMGO of NMDA-induced substance P release.
First, the Garz on mechanism predicts that inhibiting PKC will promote MOR/NMDA receptor association, increasing the inhibitory effect of DAMGO on NMDA-induced substance P release. To detect effects on the potency of DAMGO we used it at 10 nM, a concentration near its IC 50 (Fig. 1 B) . The PKC inhibitors chelerythrine (10 mM) and Ro-32-0432 (1 mM) did not affect NMDAinduced substance P release and did not increase its inhibition by DAMGO (Fig. 10 H) . In fact, chelerythrine showed a trend to decrease the inhibition by 10 nM DAMGO, contrary to the prediction.
Second, the Garz on mechanism predicts that activating PKC will promote the dissociation of the MOR/NMDA receptor complex, decreasing MOR inhibition of NMDA receptor-induced substance P release. We found that the PKC activator TPPB (1 mM) strongly increased NMDA-induced substance P release (Fig. 10 I) , an effect consistent with the reported potentiating effect of PKC on NMDA receptors in primary afferent terminals (Xie et al., 2017) . TPPB did not affect inhibition by 10 nM DAMGO (Fig. 10 I) . Phorbol 12-myristate 13-acetate (1 mM) produced similar results, although not statistically significant (Fig. 10 I) . Again, these results do not support the prediction made by the Garz on mechanism.
Therefore, our results do not support the idea that PKCregulated physical association of MORs and NMDA receptors mediates MOR inhibition of NMDA receptors in primary afferent terminals. However, we found evidence that PKC activation increases NMDA receptor function in primary afferents, which needs to be addressed in future studies.
An additional possibility is an effect of MORs on substance P release machinery, suggested by the finding that DAMGO moderately decreased vesicle exocytosis from Ad-fiber terminals, but not C-fiber terminals (Heinke et al., 2011) . However, the fact that DAMGO did not inhibit capsaicin-induced substance P release argues against MORs having any major effect on the release machinery.
2.12. Interaction between the NMDA receptor potentiating effects of PKA and BDNF We previously reported that NMDA-induced substance P release is increased by BDNF (Chen et al., 2014) acting on a truncated form of trkB receptors (Baxter et al., 1997; Fenner, 2012) present in DRG neurons (Chen et al., 2014; Ernfors et al., 1993; Lee et al., 1999) . This effect of BDNF seems to be mediated by Src family kinase (SFK) phosphorylation of the NMDA receptors at Tyr 1472 of the NR2B subunit , because incubating DRG neurons with BDNF increased Tyr 1472 phosphorylation (Chen et al., 2014) .
To investigate how this potentiating effect of BDNF relates to the inhibition by MORs and phosphorylation by PKA, spinal cord slices were preincubated for 60 min with 20 ng/ml BDNF prior to the 2 min incubation with NMDA þ D-Ser. This increased NMDAinduced NK1R internalization (compare the controls of Fig. 10 G and Fig. 10 H) , although the effect was not as pronounced as that produced by BDNF in vivo (Fig. 3) . This potentiating effect of BDNF did not preclude the inhibition by 1 mM DAMGO, 100 mM SQ22536 or 10 mM KT5720, when they were added during the 60 min incubation with BDNF (Fig. 10 H) .
The inhibitor of protein tyrosine phosphatases BVT948 (Liljebris et al., 2004 ) also increases NMDA-induced substance P release, likely by reducing the dephosphorylation of Tyr 1472 and thus increasing the effect of SFKs. Again, we determined whether this effect of BVT948 precludes the inhibition by MORs or by AC and PKA inhibitors. Preincubating the slices for 60 min with 10 mM BVT948 substantially increased NMDA-induced NK1R internalization (compare the controls of Fig. 10 G and Fig. 10 I) . Inhibition by 1 mM DAMGO, 100 mM SQ22536 and 10 mM KT5720 (added during the 60 min preincubation with BVT948) still occurred (Fig. 10 I) , although to a lesser extent than in the absence of BVT948. Taken together, results in Fig. 10H and I indicate that NR2B phosphorylation at Ser 1166 by PKA and at Tyr 1472 by SFKs potentiate NMDA receptor function independently of each other.
Physiological role
The interaction between NMDA receptors and AC-PKA signaling in primary afferents plays a major role in the maintenance of chronic pain. Thus, in the latent sensitization model of chronic pain (Marvizon et al., 2015) NMDA receptors, AC and PKA in the spinal cord are required for the maintenance of hyperalgesia (Corder et al., 2013) . In this model, substance P and NK1Rs also contribute to hyperalgesia (Rivat et al., 2009 ). Conversely, MORs in the spinal cord continuously suppress the hyperalgesia in latent sensitization (Walwyn et al., 2016) . The fact that a 2A adrenergic receptors, which are exclusively located in primary afferent terminals (Stone et al., 1998) , also suppress the hyperalgesia suggests the mechanisms of latent sensitization are located in primary afferents. All this indicates that suppression of hyperalgesia by MORs during chronic pain involves their inhibition of NMDA receptors in primary afferent terminals.
Conclusions
This study shows that MORs strongly inhibit NMDA receptorinduced substance P release from the central terminals of primary afferents. This inhibition is mediated by two mechanisms. The first is inactivation of Cav2 channels, which partly mediate the release of substance P triggered by the NMDA receptors. The second is inhibition of AC, since AC and PKA signaling is required by these NMDA receptors. Most of them have the NR2B subunit, which undergoes activating phosphorylation by PKA. In contrast, TRPV1-induced substance P release is not inhibited by MORs because it occurs independently of Cav2 channel opening. MOR inhibition and PKA activation of these NMDA receptors occurs independently of the potentiating effect of BDNF and SFKs on them.
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